Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Xanthogranuloma, Juvenile

ClinicalTrials.gov lists 3 trials for Xanthogranuloma, Juvenile or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.

MeSH D014972 Hemic and Lymphatic Diseases C15 C17 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Trials started per year Trials started per year 3 Trials by phase Trials by phase 1 Trials by recruitment status Trials by recruitment status 2 Lead sponsors Lead sponsors 1 Serious adverse events in this condition's trials Serious adverse events in this condition's trials 3 Publications Publications 3 Prevalence Prevalence 6 Rare-disease identity Rare-disease identity 2 Trials started per year Trials started per year 3 Trials by phase Trials by phase 1 Trials by recruitment status Trials by recruitment status 2 Lead sponsors Lead sponsors 1 Serious adverse events in this condition's trials Serious adverse events in this condition's trials 3 Publications Publications 3 Prevalence Prevalence 6 Rare-disease identity Rare-disease identity 2

Rows recorded per section

1 section measured, none recorded · 1 not measured yet · 1 not computed

3 of the 3 trials are tagged with Xanthogranuloma, Juvenile itself; the rest are tagged with a narrower condition beneath it.

Get the Xanthogranuloma, Juvenile report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Xanthogranuloma, Juvenile trials start? (3)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 2

Top of scale: 1

2017: 1 trials (Phase 2 1) 2021: 1 trials (Phase 2 1) 2024: 1 trials (Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2024 1
2021 1
2017 1

No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Xanthogranuloma, Juvenile trials in? (1)

Shown in this order: phase order.

Trials by phase
Phase Trials
Phase 2 3

How many Xanthogranuloma, Juvenile trials are recruiting? (2)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 2
Active, not recruiting 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Xanthogranuloma, Juvenile trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 1

Which serious adverse events do Xanthogranuloma, Juvenile trials report? (3)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Infections and infestations - Other, specify 1 1
Laryngeal edema 1 1
Meningitis 1 1

Which publications cover Xanthogranuloma, Juvenile? (3)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014 No
Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatric blood & cancer 2005 No
Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. The Journal of pediatrics 1975 No

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Juvenile xanthogranuloma Point prevalence <1 / 1 000 000 Germany Not stated Unspecified
Juvenile xanthogranuloma Point prevalence <1 / 1 000 000 Germany Not stated Exact
Juvenile xanthogranuloma Annual incidence <1 / 1 000 000 Germany Not stated Exact
Juvenile xanthogranuloma Annual incidence <1 / 1 000 000 Germany Not stated Exact
Juvenile xanthogranuloma Annual incidence <1 / 1 000 000 Germany Not stated Unspecified

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Juvenile xanthogranuloma 158000 Exact Orphanet Rare Disease Ontology (ORDO)
Juvenile xanthogranuloma 158000 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Not computed for conditions with fewer than 10 trials: drugs tested.

Browse all condition evidence pages